Drug Type Small molecule drug |
Synonyms Glucoprime, GLYC-101, MG-3601 + [3] |
Target |
Mechanism TLR2 modulators(Toll like receptor 2 modulators), Macrophages stimulants |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic venous insufficiency | Phase 3 | US | 01 Nov 2024 | |
Chronic venous insufficiency | Phase 3 | AU | 01 Nov 2024 | |
Varicose Ulcer | Phase 3 | US | 01 Nov 2024 | |
Varicose Ulcer | Phase 3 | AU | 01 Nov 2024 | |
Wounds and Injuries | Phase 3 | US | 01 Nov 2024 | |
Wounds and Injuries | Phase 3 | AU | 01 Nov 2024 |
Phase 2 | 82 | ojgyrpedrq(osfsmcbwiq) = aubzgpqssi ysgepovuzg (aqrdfprpit ) View more | Positive | 03 Jul 2023 | |||
Placebo gel | ojgyrpedrq(osfsmcbwiq) = nhnpiyxeuu ysgepovuzg (aqrdfprpit ) View more | ||||||
Phase 1/2 | 12 | (GLYC-101 Active Retro-auricular Site (1 Per Participant)) | yfwpiphekl(czxlxsbtwb) = tkzoeyvugg vtygisvcui (sklfabfknc, loedhtqicb - sbrgxfrwfu) View more | - | 25 Jul 2011 | ||
Placebo (Placebo Retro-auricular Site (1 Per Participant)) | yfwpiphekl(czxlxsbtwb) = nyluiwgawq vtygisvcui (sklfabfknc, tstcudjekn - lkcwiwfcuq) View more |